These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


357 related items for PubMed ID: 33973373

  • 1. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
    Jongen VW, Hoornenborg E, van den Elshout MA, Boyd A, Zimmermann HM, Coyer L, Davidovich U, Anderson PL, de Vries HJ, Prins M, Schim van der Loeff MF, Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative.
    J Int AIDS Soc; 2021 May; 24(5):e25708. PubMed ID: 33973373
    [Abstract] [Full Text] [Related]

  • 2. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
    van den Elshout MA, Hoornenborg E, Coyer L, Anderson PL, Davidovich U, de Vries HJ, Prins M, Schim van der Loeff MF, of the Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative (H-TEAM).
    Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
    [Abstract] [Full Text] [Related]

  • 3. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
    Songtaweesin WN, Kawichai S, Phanuphak N, Cressey TR, Wongharn P, Saisaengjan C, Chinbunchorn T, Janyam S, Linjongrat D, Puthanakit T, CE-PID - TRC Adolescent Study Team.
    J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
    [Abstract] [Full Text] [Related]

  • 4. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, Goulart S, Torres TS, Marins LMS, Anderson PL, Luz PM, Costa Leite ID, Liu AY, Veloso VG, Grinsztejn B, PrEP Brasil Study TeamClinical Trial Number 01989611.
    J Int AIDS Soc; 2017 Apr 06; 20(1):21472. PubMed ID: 28418232
    [Abstract] [Full Text] [Related]

  • 5. Sexual behaviour and incidence of sexually transmitted infections among men who have sex with men (MSM) using daily and event-driven pre-exposure prophylaxis (PrEP): Four-year follow-up of the Amsterdam PrEP (AMPrEP) demonstration project cohort.
    van den Elshout MAM, Wijstma ES, Boyd A, Jongen VW, Coyer L, Anderson PL, Davidovich U, de Vries HJC, Prins M, Schim van der Loeff MF, Hoornenborg E, Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative (H-TEAM).
    PLoS Med; 2024 May 06; 21(5):e1004328. PubMed ID: 38718068
    [Abstract] [Full Text] [Related]

  • 6. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project.
    Wijstma ES, Jongen VW, Boyd A, van den Elshout MAM, de Vries HJC, Davidovich U, Anderson PL, Prins M, Hoornenborg E, Schim van der Loeff MF.
    AIDS; 2024 Jul 01; 38(8):1248-1256. PubMed ID: 38518076
    [Abstract] [Full Text] [Related]

  • 7. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence.
    Vuylsteke B, Reyniers T, De Baetselier I, Nöstlinger C, Crucitti T, Buyze J, Kenyon C, Wouters K, Laga M.
    J Int AIDS Soc; 2019 Oct 01; 22(10):e25407. PubMed ID: 31663257
    [Abstract] [Full Text] [Related]

  • 8. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L, Niu X, Brunelli MK, Mugwanya KK.
    Curr HIV/AIDS Rep; 2024 Oct 01; 21(5):264-281. PubMed ID: 39120667
    [Abstract] [Full Text] [Related]

  • 9. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
    Hoornenborg E, Achterbergh RC, van der Loeff MFS, Davidovich U, van der Helm JJ, Hogewoning A, van Duijnhoven YT, Sonder GJ, de Vries HJ, Prins M, Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative.
    J Int AIDS Soc; 2018 Mar 01; 21(3):e25105. PubMed ID: 29603900
    [Abstract] [Full Text] [Related]

  • 10. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
    Goldwirt L, Bauer R, Liegeon G, Charreau I, Delaugerre C, Cotte L, Pialou G, Cua E, Laghzal A, Buschman L, Anderson PL, Mourah S, Meyer L, Molina JM, ANRS IPERGAY Study Group.
    J Antimicrob Chemother; 2021 Sep 15; 76(10):2675-2680. PubMed ID: 34278433
    [Abstract] [Full Text] [Related]

  • 11. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG, PrEP Brasil Study Team.
    Lancet HIV; 2018 Mar 15; 5(3):e136-e145. PubMed ID: 29467098
    [Abstract] [Full Text] [Related]

  • 12. Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis - a qualitative analysis.
    Zimmermann HM, Eekman SW, Achterbergh RC, Schim van der Loeff MF, Prins M, de Vries HJ, Hoornenborg E, Davidovich U, Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Consortium (H-TEAM).
    J Int AIDS Soc; 2019 Oct 15; 22(10):e25389. PubMed ID: 31612621
    [Abstract] [Full Text] [Related]

  • 13. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.
    Hoornenborg E, Coyer L, Achterbergh RCA, Matser A, Schim van der Loeff MF, Boyd A, van Duijnhoven YTHP, Bruisten S, Oostvogel P, Davidovich U, Hogewoning A, Prins M, de Vries HJC, Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam (H-TEAM) Initiative.
    Lancet HIV; 2019 Jul 15; 6(7):e447-e455. PubMed ID: 31178284
    [Abstract] [Full Text] [Related]

  • 14. "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
    Kimani M, van der Elst EM, Chirro O, Wahome E, Ibrahim F, Mukuria N, de Wit TFR, Graham SM, Operario D, Sanders EJ.
    PLoS One; 2021 Jul 15; 16(1):e0244226. PubMed ID: 33465090
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study.
    Wheeler DP, Fields SD, Beauchamp G, Chen YQ, Emel LM, Hightow-Weidman L, Hucks-Ortiz C, Kuo I, Lucas J, Magnus M, Mayer KH, Nelson LE, Hendrix CW, Piwowar-Manning E, Shoptaw S, Watkins P, Watson CC, Wilton L.
    J Int AIDS Soc; 2019 Feb 15; 22(2):e25223. PubMed ID: 30768776
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV, Das M, Dunn DT, Ebrahimi R, Zhao Y, Stirrup OT, Baeten JM, Anderson PL.
    J Int AIDS Soc; 2021 May 15; 24(5):e25744. PubMed ID: 34021709
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.